Market Exclusivity
A period during which no competing generic or biosimilar product can be approved for the same indication, regardless of patent status. Orphan drug market exclusivity (7 years US, 10 years EU) is the most common form. Market exclusivity provides guaranteed competitive protection beyond patents.
Technical Context
Forms of market exclusivity: orphan drug (7 years US, 10 years EU — blocks approval of the same drug for the same orphan indication), paediatric exclusivity (6-month extension added to all existing patents and exclusivities for conducting FDA-requested paediatric studies), new chemical entity exclusivity (5 years US — prevents ANDA submission referencing the drug), and qualified infectious disease product exclusivity (QIDP, 5-year extension for certain antibiotics — relevant to antimicrobial peptides like dalbavancin, oritavancin). Market exclusivity provides a legally enforced competitive moat independent of patents. For peptide drugs with orphan designations, the 7-10 year market exclusivity can be the most valuable protection, particularly for natural peptide sequences that may face patent limitations.